Please login to the form below

trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

AZ’s bet on Daiichi’s rival to Kadcyla pays off

The two partners have reported top-line data from the pivotal phase 2 DESTINY-Breast01 study showing that DS-8201 (trastuzumab deruxtecan) met its primary objective in HER2-positive breast cancer ... patients who had failed or discontinued treatment with

Latest news

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

The $6.9bn deal, funded in part by an equity placement of approximately $3.5bn, includes a sizeable $1.35bn upfront payment which reflects the fact that the ADC – trastuzumab deruxtecan ... DS-8201 is currently in phase 3 testing for HER2-positive
Roche preps new Kadcyla filings after phase 3 trial win

In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,
Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

The Japanese drugmaker’s has started recruiting patients into two pivotal trials of its ADC trastuzumab deruxtecan (DS-8201), one of which will pit the drug against Kadcyla (ado-trastuzumab emtansine) ... in HER2 positive, unresectable and/or
AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
NICE relents on Kadcyla after Roche pricing negotiations

The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that

More from news
Approximately 5 fully matching, plus 44 partially matching documents found.

Latest Intelligence

An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager – Healthcare advertising: Salary TBC

Events Executive: DOE

Senior Medical Writer: Competitive salary plus benefits

Client Services Director- Flexible Working: Negotiable

Account Director – UK Office: Excellent salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...